NDA 215395 · Invagen Pharms
Lanreotide Acetate
Lanreotide Acetate · Subcutaneous
DiscontinuedLast checked: Nov 20, 2026Latest source record: Sep 16, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2021
Dec 17, 2021
Approved uses
2
Original approval plus efficacy supplements
Registered trials
84
39 Phase 3, 6 recruiting
FAERS reports
3,387
3,167 serious, 1,185 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 1, 2024.
Lanreotide Injection is a somatostatin analog indicated for: the long-term treatment of acromegalic patients who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy. ( 1.1 ) the treatment of adult patients with unresectable, well- or moderately- differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival. ( 1.2 ) the treatment of adults with carcinoid syndrome; when used, it reduces the frequency of short-acting somatostatin analog rescue therapy. ( 1.3 ) 1.1 Acromegaly Lanreotide Injection is indicated for the long-term treatment of acromegalic patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy is not an option. The goal of treatment in acromegaly is to reduce growth hormone (GH) and insulin growth factor-1 (IGF-1) levels to normal. 1.2 Gastroenteropancreatic Neuroendocrine Tumors Lanreotide Injection is indicated for the treatment of adult patients with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival. 1.3 Carcinoid Syndrome Lanreotide Injection is indicated for the treatment of adults with carcinoid syndrome; when used, it reduces the frequency of short-acting somatostatin analog rescue therapy.
Mechanism: Lanreotide, the active component of Lanreotide Injection, is an octapeptide analog of natural somatostatin. The mechanism of action of lanreotide is believed to be similar to that of natural somatostatin.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 16, 2024 Supplement 7 · Efficacy LetterLabel
- Dec 17, 2021 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
3 products under this application
- LANREOTIDE ACETATE · LANREOTIDE ACETATE EQ 60MG BASE/0.2ML (EQ 60MG BASE/0.2ML) · SOLUTION, SUBCUTANEOUS · Discontinued
- LANREOTIDE ACETATE · LANREOTIDE ACETATE EQ 90MG BASE/0.3ML (EQ 90MG BASE/0.3ML) · SOLUTION, SUBCUTANEOUS · Discontinued
- LANREOTIDE ACETATE · LANREOTIDE ACETATE EQ 120MG BASE/0.5ML (EQ 120MG BASE/0.5ML) · SOLUTION, SUBCUTANEOUS · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Lanreotide" as an intervention, any sponsor and status, largest first.
- Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA TherapyPivotal-lookingActive, not recruiting
RayzeBio, Inc.Industry
NCT05477576 · 343 participants · Start Mar 24, 2022 · Primary completion Dec 2026
Drug: RYZ101; Everolimus and 3 more · For: GEP-NET; Gastroenteropancreatic Neuroendocrine Tumor; Gastroenteropancreatic Neuroendocrine Tumor Disease and 4 more
Sites: Phoenix, Arizona; Duarte, California; Irvine, California · 54 sites in all
- A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NETPivotal-lookingActive, not recruiting
Camurus ABIndustry
NCT05050942 · 332 participants · Start Oct 22, 2021 · Primary completion Nov 2026
Drug: CAM2029; Octreotide LAR and 1 more · For: Gastro-enteropancreatic Neuroendocrine Tumor
Sites: Phoenix, Arizona; Santa Monica, California; Denver, Colorado · 86 sites in all
- Study of Lanreotide to Treat Polycystic Kidney DiseasePivotal-lookingStatus unknown
University Medical Center GroningenAcademic, hospital or other
NCT01616927 · 300 participants (planned) · Start Jun 2012 · Primary completion Aug 2017
Drug: Lanreotide · For: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Sites: Groningen, Netherlands; Leiden, Netherlands; Nijmegen, Netherlands · 4 sites in all
- Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic FistulaPivotal-lookingRecruiting
SWOG Cancer Research NetworkResearch network
NCT06807437 · 274 participants (planned) · Start May 9, 2025 · Primary completion Apr 1, 2029
Drug: Lanreotide · For: Pancreatic Carcinoma; Pancreatic Neoplasm
Sites: Birmingham, Alabama; Daphne, Alabama; Fairhope, Alabama · 118 sites in all
- Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtientsPivotal-lookingRecruiting
University Hospital, AntwerpAcademic, hospital or other
NCT05701241 · 270 participants (planned) · Start Jun 28, 2023 · Primary completion Apr 2029
Drug: Somatostatin analog · For: Gastroenteropancreatic Neuroendocrine Tumor
Sites: Brasschaat, Belgium; Rumst, Belgium; Ghent, Belgium · 19 sites in all
- Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine TumoursPivotal-lookingCompleted
IpsenIndustry
NCT00353496 · 264 participants · Start Jun 2006 · Primary completion Apr 2013
Drug: lanreotide (Autogel formulation); Placebo · For: Endocrine Tumors
Sites: Los Angeles, California; Iowa City, Iowa; Baltimore, Maryland · 71 sites in all
- Somatostatin Analogues vs. Observation After Peptide Receptor Radionuclide Therapy (PRRT) in Nonfunctional Neuroendocrine NeoplasmsPivotal-lookingRecruiting
Washington University School of MedicineAcademic, hospital or other
NCT07842172 · 240 participants (planned) · Start Nov 2, 2026 · Primary completion Nov 30, 2034
Drug: Somatostatin Analogue(s) · For: Neuroendocrine Neoplasm; Gastroenteropancreatic Neuroendocrine Neoplasm
Sites: San Francisco, California; St Louis, Missouri
- Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled AcromegalyPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT01137682 · 198 participants · Start Jul 19, 2010 · Primary completion Jan 22, 2013
Drug: Pasireotide; octreotide LAR 30mg and 1 more · For: Acromegaly
Sites: Ann Arbor, Michigan; Portland, Oregon; Dallas, Texas · 60 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death1,038
- off label use943
- diarrhoea596
- fatigue454
- abdominal pain347
- nausea328
- malignant neoplasm progression327
- weight decreased281
- malaise270
- asthenia269
- dizziness237
- vomiting234
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2006 | 2 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 3 |
| 2013 | 3 |
| 2014 | 3 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 6 |
| 2018 | 29 |
| 2019 | 41 |
| 2020 | 58 |
| 2021 | 198 |
| 2022 | 338 |
| 2023 | 868 |
| 2024 | 666 |
| 2025 | 753 |
| 2026 | 413 |
Recalls
2 FDA enforcement reports for this application.
Mar 13, 2026 · Class II · Ongoing
Lack of Assurance of Sterility: Due to an FDA observation at the contract manufacturing site for deficiencies in their visual inspection procedure.
Jan 2, 2026 · Class II · Ongoing
Presence of Particulate Matter.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Lanreotide Acetate (Lanreotide Acetate)
2024 spending
$8.7M
Beneficiaries
187
1,030 claims
Per beneficiary
$46,719
$16,248.29 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $1,587,960 |
| 2023 | $6,935,856 |
| 2024 | $8,736,380 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
Caplin ME, Pavel M, jwika JB, et al. · N Engl J Med 2014 · Clinical Trial, Phase III, Multicenter Study
- ACROBAT Edge: Safety and Efficacy of Switching Injected SRLs to Oral Paltusotine in Patients With Acromegaly.
Gadelha MR, Gordon MB, Doknic M, et al. · J Clin Endocrinol Metab 2023 · Clinical Trial, Multicenter Study
- Acromegaly Disease Control Maintained After Switching From Injected Somatostatin Receptor Ligands to Oral Paltusotine.
Gadelha MR, Casagrande A, Strasburger CJ, et al. · J Clin Endocrinol Metab 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Effectiveness and predictors of response to somatostatin analogues in patients with gastrointestinal angiodysplasias: a systematic review and individual patient data meta-analysis.
Goltstein LCMJ, Grooteman KV, Rocco A, et al. · Lancet Gastroenterol Hepatol 2021 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Circulating tumour cells and tumour biomarkers in functional midgut neuroendocrine tumours.
Meyer T, Caplin M, Khan MS, et al. · J Neuroendocrinol 2022 · Clinical Trial, Phase IV, Research Support, Non-U.S. Gov't
- Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors.
Grenader T, Pavel ME, Ruszniewski PB, et al. · Anticancer Drugs 2020 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Invagen Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.